Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation

Pozo, Eduardo; Castellano, José M.; Kanwar, Anubhav; Deochand, Rajiv; Castillo-Martin, Mireia; Pazos-López, Pablo; González-Lengua, Carlos; Osman, Keren; Cham, Matthew D.; Cordon‐Cardo, Carlos; Narula, Jagat; Fuster, Valentín; Sanz, Javier

doi:10.1016/j.cardfail.2017.08.445

Cited by 9 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is provided in Table 1 8–25,34–77 . A graphical representation of the prevalence of cardiac amyloidosis across various populations subgroups is provided in Figure (and online supplementary Figure – focused version).…”

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Antonopoulos

Panagiotopoulos

Kouroutzoglou

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Antonopoulos

Panagiotopoulos

Kouroutzoglou

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…3 ) [ 51 ]. A technique that attempts to quantify the LGE findings, the Look-Locker magnetic resonance sequence, was tested in real-life patient series and yielded mixed results [ 52 ]. Higher T1 inversion times (roughly the time it takes for T1 signals to drop to pre-contrast levels) correlated with amyloid load but not patient prognosis.…”

Section: Resultsmentioning

confidence: 99%

Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

Kyriakou

Mouselimis

Tsarouchas

et al. 2018

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundCardiac Amyloidosis (CA) pertains to the cardiac involvement of a group of diseases, in which misfolded proteins deposit in tissues and cause progressive organ damage. The vast majority of CA cases are caused by light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). The increased awareness of these diseases has led to an increment of newly diagnosed cases each year.MethodsWe performed multiple searches on MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews. Several search terms were used, such as “cardiac amyloidosis”, “diagnostic modalities cardiac amyloidosis” and “staging cardiac amyloidosis”. Emphasis was given on original articles describing novel diagnostic and staging approaches to the disease.ResultsImaging techniques are indispensable to diagnosing CA. Novel ultrasonographic techniques boast high sensitivity and specificity for the disease. Nuclear imaging has repeatedly proved its worth in the diagnostic procedure, with efforts now focusing on standardization and quantification of amyloid load. Because the latter would be invaluable for any staging system, those spearheading research in magnetic resonance imaging of the disease are also trying to come up with accurate tools to quantify amyloid burden. Staging tools are currently being developed and validated for ATTR CA, in the spirit of the acclaimed Mayo Staging System for AL.ConclusionCardiac involvement confers significant morbidity and mortality in all types of amyloidosis. Great effort is made to reduce the time to diagnosis, as treatment in the initial stages of the disease is tied to better prognosis. The results of these efforts are highly sensitive and specific diagnostic modalities that are also reasonably cost effective.

show abstract

“…The consequent T1 ratios are correlated with the amyloid burden. Considering multiple confounding factors, this method has proven to be a simple way to standardize myocardial T1 values 74 …”

Section: Parametric Mappingmentioning

confidence: 99%

“…Considering multiple confounding factors, this method has proven to be a simple way to standardize myocardial T1 values. 74 T1 mapping can detect diffuse myocardial involvement of CA, especially in combination with LVEF and wall thickness. In systemic amyloidosis, a large proportion of patients with cardiac involvement also suffer renal impairment.…”

Section: Parametric Mappingmentioning

confidence: 99%

State of the Art: Quantitative Cardiac MRI in Cardiac Amyloidosis

Guo

2022

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Cardiac amyloidosis (CA) is characterized by amyloid infiltration in the myocardial extracellular space, causing heart failure. Patients with CA are currently underdiagnosed. Cardiac involvement is significantly associated with the prognosis and treatment decision‐making for CA. Early identification and accurate stratification are the crucial first step in patient management. Comprehensive cardiac MRI‐based evaluation of the cardiac structure, function, and myocardial tissue characterization assesses cardiac involvement by tracing disease processes. Emerging quantitative tissue characterization techniques have introduced new measures that can identify early staged CA and monitor disease progression or response after treatment. Quantitative cardiac MRI is becoming an instrumental tool in understanding CA, which leads to changes in individualized patient care. This review aimed to discuss the quantitative cardiac MRI‐based assessment of CA using established and emerging techniques. Evidence Level 5 Technical Efficacy Stage 3

show abstract

Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation

Cited by 9 publications

References 31 publications

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

State of the Art: Quantitative Cardiac MRI in Cardiac Amyloidosis

Contact Info

Product

Resources

About